BeiGene Ltd (FRA:49BA)
€ 152 5 (3.4%) Market Cap: 15.89 Bil Enterprise Value: 14.29 Bil PE Ratio: 0 PB Ratio: 5.23 GF Score: 69/100

Beigene Ltd China National Reimbursement Drug List (NRDL) Results Conference Call Transcript

Dec 29, 2020 / 12:00AM GMT
Release Date Price: €204 (-1.92%)
Craig West
BeiGene, Ltd. - Senior Director of IR

Hello, everyone, and welcome to BeiGene's 2020 NRDL Results Conference Call. My name is Craig West, and I'm the Head of Investor Relations here at BeiGene. After the presentation, we will take questions from the audience. (Operator Instructions)

As a reminder, today's call will be recorded.

I would now like to introduce your host for today's conference, Dr. Howard Liang, Chief Financial Officer and Chief Strategy Officer of BeiGene. Howard? You may begin.

Heng Liang
BeiGene, Ltd. - CFO & Chief Strategy Officer

Thank you, Craig, and welcome to all of you joining us from around the globe. On today's call, we'll discuss the inclusion of 3 of BeiGene's innovative oncology products on China's National Reimbursement Drug List or NRDL and implications to our company and in the markets we serve.

Today, our CEO, John Oyler, will start us off with an introduction to put the reimbursement listing outcomes into the context of our overall mission and strategy and our recent progress. We'll

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot